Is the Etoposide, Doxorubicin, and Cisplatin Plus Mitotane Regimen Able to Prolong Survival in Patients With Metastatic Adrenocortical Carcinoma?. // Endocrine Practice. – URL: https://www.sciencedirect.com/science/article/pii/S1530891X26009778?dgcid=rss_sd_all
Is the Etoposide, Doxorubicin, and Cisplatin Plus Mitotane Regimen Able to Prolong Survival in Patients With Metastatic Adrenocortical Carcinoma?. Endocrine Practice. https://www.sciencedirect.com/science/article/pii/S1530891X26009778?dgcid=rss_sd_all
“Is the Etoposide, Doxorubicin, and Cisplatin Plus Mitotane Regimen Able to Prolong Survival in Patients With Metastatic Adrenocortical Carcinoma?.” Endocrine Practice.
@article{article93725,
title = {Is the Etoposide, Doxorubicin, and Cisplatin Plus Mitotane Regimen Able to Prolong Survival in Patients With Metastatic Adrenocortical Carcinoma?},
journal = {Endocrine Practice},
url = {https://www.sciencedirect.com/science/article/pii/S1530891X26009778?dgcid=rss_sd_all}
}